Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
9/23/26 Roche (RO) RG6299 for Immunoglobulin A (IgA) Nephropathy (Berger's Disease) Subscribers Only Subscribers Only Subscribers Only
9/22/26 Roche (RO) enicepatide for Obesity Subscribers Only Subscribers Only Subscribers Only
9/22/26 Roche (RO) enicepatide for Diabetes Mellitus, Type II Subscribers Only Subscribers Only Subscribers Only
9/22/26 VistaGen Therapeutics (VTGN) fasedienol for Social Anxiety Disorder (SAD) Subscribers Only Subscribers Only Subscribers Only
9/15/26 BioVie (BIVI) bezisterim for COVID-19 Treatment Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
07/31/2025 Subscribers Only Subscribers Only Regulatory - sNDA/sBLA Filing
09/30/2025 Subscribers Only Subscribers Only Trial Announcement - Trial Completion
10/28/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
10/31/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
11/11/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update